---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-018562"
form_type: "8-K"
ticker: "VVOS"
cik: "0001716166"
company_name: "Vivos Therapeutics, Inc."
filed_at: "2026-04-22T23:59:59+00:00"
generated_at: "2026-05-15T04:54:39.246803+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Vivos Therapeutics gets Nasdaq delisting notice for negative equity of $1.55M

## Summary
- Negative stockholders' equity of ~$1.55M as of Dec 31, 2025, below Nasdaq's $2.5M minimum requirement.
- Nasdaq letter received April 17, 2026; Company must submit compliance plan by June 1, 2026.
- Raised $6.8M in Q1 2026: $4.6M warrant exercise inducement + $2.25M private placement with existing investor.
- If plan accepted, Nasdaq may grant extension to Oct 14, 2026; failure to regain compliance risks delisting.
- No immediate impact on common stock listing; Company intends to submit plan timely.

## SEC filing metadata
- accession: 0001493152-26-018562
- form_type: 8-K
- ticker: VVOS
- cik: 0001716166
- company_name: Vivos Therapeutics, Inc.
- filed_at: 2026-04-22T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1716166/000149315226018562/0001493152-26-018562-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716166/000149315226018562/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-018562
- JSON: https://secwatch.observer/filing/0001493152-26-018562.json
- Plain text: https://secwatch.observer/filing/0001493152-26-018562.txt

## Source-grounded claims
- claim_id: fee6a682ec61b3b60f83bec73bf28d6648c1352e
  claim: Vivos Therapeutics, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
  evidence_excerpt: April 17, 2026, Vivos Therapeutics, Inc. (the “Company”) received a letter (“Letter”) from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company’s stockholde
  evidence_url: https://www.sec.gov/Archives/edgar/data/1716166/000149315226018562/0001493152-26-018562-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.